- Report
- July 2025
- 175 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- February 2025
- 100 Pages
Global
From €5321EUR$5,950USD£4,626GBP
- Report
- August 2025
- 149 Pages
Global
From €2682EUR$2,999USD£2,332GBP
- Report
- April 2025
- 200 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- October 2025
- 371 Pages
Global
From €5232EUR$5,850USD£4,548GBP
- Report
- September 2025
- 250 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- October 2025
- 194 Pages
Global
From €3171EUR$3,545USD£2,756GBP
€3523EUR$3,939USD£3,062GBP
- Report
- September 2025
Global
From €4382EUR$4,900USD£3,810GBP
- Report
- December 2024
- 200 Pages
Global
From €3354EUR$3,750USD£2,916GBP
- Report
- March 2025
- 175 Pages
Global
From €4016EUR$4,490USD£3,491GBP
- Report
- August 2025
- 145 Pages
Global
From €3533EUR$3,950USD£3,071GBP
- Report
- May 2025
- 82 Pages
Global
From €3500EUR$4,192USD£3,149GBP
- Report
- April 2025
- 150 Pages
Global
From €3443EUR$3,850USD£2,993GBP
€4338EUR$4,850USD£3,771GBP
- Book
- March 2021
- 400 Pages
From €148EUR$165USD£128GBP
- Book
- March 2019
North America

Celiac Disease is a chronic autoimmune disorder of the digestive system that is caused by an adverse reaction to gluten, a protein found in wheat, barley, and rye. It is classified as an allergy and immunology disorder, as it is triggered by an immune response to gluten. Symptoms of Celiac Disease include abdominal pain, bloating, diarrhea, and weight loss. Treatment involves a strict gluten-free diet, which can be difficult to maintain.
The Celiac Disease market is composed of companies that provide products and services related to the diagnosis, treatment, and management of the disorder. These include pharmaceutical companies that develop and market drugs to treat the condition, as well as companies that provide gluten-free food products and services. Additionally, there are companies that provide diagnostic tests and other medical services related to Celiac Disease.
Some companies in the Celiac Disease market include GlaxoSmithKline, Novartis, Pfizer, AbbVie, and Celimmune. Show Less Read more